BIOMAT Database Logo BIOMAT Database Logo

Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. 2004

Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy.

OBJECTIVE To evaluate circulating levels of ghrelin and adiponectin (ApN) in GH-deficient (GHD) adults before and after short- and long-term recombinant human GH (rhGH) administration. METHODS Twenty-three patients were studied. Seventeen subjects (Group A, 12 men, five women) were evaluated at baseline and after 1 year rhGH therapy (dose mean +/- SD: 0.3 +/- 0.1 mg/day) with the assessment of serum IGF-I, ghrelin, ApN, leptin, insulin and glucose levels, percentage of body fat (BF%), HOMA-IR and QUICKI. Seventeen age-, sex- and body mass index (BMI)-matched healthy subjects were recruited for comparisons. Six patients (Group B, three men, three women) underwent IGF-I generation test (rhGH 0.025 mg/kg/day for 7 days), blood sampled at baseline and on day 8 for determination of IGF-I, ghrelin and ApN levels. RESULTS Group A: at baseline GHD patients showed low IGF-I levels and BF% significantly higher than controls (31.4 +/- 2.5 vs. 26.4 +/- 1.3, P < 0.05). Glucose, insulin, leptin, tryglicerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels, as well as HOMA-IR and QUICKI values were similar in the two series, while total cholesterol levels were higher in GHD. In GHD, ghrelin levels were significantly lower than in controls (193.9 +/- 27.1 vs. 298.1 +/- 32.5 pmol/l, respectively, P = 0.02), while ApN levels were similar (10.2 +/- 1.1 and 9 +/- 1 mg/l, respectively, P = ns). After 1 year of rhGH therapy, BF%, BMI, serum total and LDL cholesterol significantly decreased, serum leptin levels showed a trend to decrease, while HOMA-IR and QUICKI did not change. Ghrelin and ApN levels significantly increased from 193.9 +/- 27.1 to 232.4 +/- 26.3 pmol/l (P < 0.01) and from 8.6 +/- 0.8 to 10.3 +/- 1.1 mg/l (P < 0.05), respectively. In group B, the expected increase in IGF-I levels was associated with a significant decrease in ghrelin levels, while ApN did not change. CONCLUSIONS GHD patients showed serum ghrelin lower than controls, probably due to the higher BF%. No difference in ApN was observed. Ghrelin and ApN increments induced by long-term treatment may be related to the significant BMI and BF% reduction that is the predominant metabolic effect of rhGH therapy. Conversely, the decrease in ghrelin levels observed after short-term rhGH administration may be consistent with an inhibitory feedback of GH and/or IGF-I on ghrelin release.

UI MeSH Term Description Entries
D007018 Hypopituitarism Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions. Adenohypophyseal Hyposecretion,Anterior Pituitary Hyposecretion Syndrome,Sheehan Syndrome,Simmonds Disease,Hyposecretion Syndrome, Anterior Pituitary,Hyposecretion, Adenohypophyseal,Pituitary Insufficiency,Postpartum Hypopituitarism,Postpartum Panhypopituitarism,Postpartum Pituitary Insufficiency,Sheehan's Syndrome,Simmonds' Disease,Disease, Simmonds,Hypopituitarism, Postpartum,Insufficiency, Pituitary,Panhypopituitarism, Postpartum,Pituitary Insufficiency, Postpartum,Sheehans Syndrome,Simmond's Disease,Syndrome, Sheehan,Syndrome, Sheehan's
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients.
November 2003, The Journal of clinical endocrinology and metabolism,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Short- and long-term effects of growth hormone (GH) replacement on protein metabolism in GH-deficient adults.
December 2003, The Journal of clinical endocrinology and metabolism,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration.
November 2006, Journal of endocrinological investigation,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults.
September 2002, Clinical endocrinology,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
COLIA1 Sp1 polymorphism: towards individualized therapy with injected recombinant hGH in GH-deficient adults?
August 2008, Pharmacogenomics,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement.
February 2014, European journal of endocrinology,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response.
September 1992, The American journal of physiology,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults.
July 2008, The Journal of clinical endocrinology and metabolism,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.
April 2008, European journal of endocrinology,
Claudia Giavoli, and Vincenzo Cappiello, and Sabrina Corbetta, and Cristina L Ronchi, and Paola S Morpurgo, and Emanuele Ferrante, and Paolo Beck-Peccoz, and Anna Spada
Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
October 2000, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!